HC Wainwright Reaffirms "Buy" Rating for Invivyd (NASDAQ:IVVD)

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD - Free Report) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Invivyd's Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.64) EPS and FY2029 earnings at $0.41 EPS.

Other analysts have also recently issued research reports about the company. EF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. D. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Invivyd in a research note on Monday, February 3rd. Finally, Morgan Stanley cut their price objective on Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $7.89.

Invivyd Trading Up 3.0 %

Shares of NASDAQ IVVD traded up $0.06 during mid-day trading on Tuesday, reaching $2.04. The company had a trading volume of 27,285,427 shares, compared to its average volume of 36,383,976. The stock has a market cap of $244.02 million, a PE ratio of -1.04 and a beta of 0.61. The company has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.85. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.10.

Insider Transactions at Invivyd

In related news, Director Terrance Mcguire sold 119,805 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $0.42, for a total transaction of $50,318.10. Following the sale, the director now directly owns 3,568,274 shares in the company, valued at $1,498,675.08. This represents a 3.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 816,466 shares of company stock valued at $423,214. Corporate insiders own 17.90% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IVVD. Barclays PLC lifted its stake in shares of Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock valued at $120,000 after purchasing an additional 75,780 shares during the period. State Street Corp raised its stake in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company's stock worth $1,039,000 after buying an additional 35,904 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the 3rd quarter valued at about $27,000. Cubist Systematic Strategies LLC raised its stake in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after purchasing an additional 31,992 shares during the period. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.